Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
This drive will expand access to quality diagnostics and help find the ‘missing millions’ – patients that are suffering from TB but not registered in the healthcare system
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Subscribe To Our Newsletter & Stay Updated
